M S Aboian1, E Tong2, D A Solomon3, C Kline4, A Gautam5, A Vardapetyan6, B Tamrazi7, Y Li8, C D Jordan8, E Felton4, B Weinberg9, S Braunstein10, S Mueller11,12,4, S Cha8. 1. From the Department of Radiology and Biomedical Imaging (M.S.A.), Yale School of Medicine, New Haven, Connecticut mariam.aboian@yale.edu. 2. Department of Radiology (E.T.), Stanford University, Stanford, California. 3. Division of Neuropathology (D.A.S.). 4. Division of Pediatric Hematology/Oncology (C.K., E.F., S.M.), Department of Pediatrics, University of California, San Francisco, California. 5. Johns Hopkins University (A.G.), Baltimore, Maryland. 6. University of California Berkeley (A.V.), Berkeley, California. 7. Department of Radiology (B.T.), Children's Hospital Los Angeles, Los Angeles, California. 8. Department of Pathology, Departments of Radiology (Y.L., C.D.J., S.C.). 9. Department of Neuroradiology (B.W.), Emory University, Atlanta, Georgia. 10. Radiation Oncology (S.B.). 11. Neurological Surgery (S.M.). 12. Neurology (S.M.).
Abstract
BACKGROUND AND PURPOSE: Diffuse midline gliomas with histone H3 K27M mutation are biologically aggressive tumors with poor prognosis defined as a new diagnostic entity in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. There are no qualitative imaging differences (enhancement, border, or central necrosis) between histone H3 wildtype and H3 K27M-mutant diffuse midline gliomas. Herein, we evaluated the utility of diffusion-weighted imaging to distinguish H3 K27M-mutant from histone H3 wildtype diffuse midline gliomas. MATERIALS AND METHODS: We identified 31 pediatric patients (younger than 21 years of age) with diffuse gliomas centered in midline structures that had undergone assessment for histone H3 K27M mutation. We measured ADC within these tumors using a voxel-based 3D whole-tumor measurement method. RESULTS: Our cohort included 18 infratentorial and 13 supratentorial diffuse gliomas centered in midline structures. Twenty-three (74%) tumors carried H3-K27M mutations. There was no difference in ADC histogram parameters (mean, median, minimum, maximum, percentiles) between mutant and wild-type tumors. Subgroup analysis based on tumor location also did not identify a difference in histogram descriptive statistics. Patients who survived <1 year after diagnosis had lower median ADC (1.10 × 10-3mm2/s; 95% CI, 0.90-1.30) compared with patients who survived >1 year (1.46 × 10-3mm2/s; 95% CI, 1.19-1.67; P < .06). Average ADC values for diffuse midline gliomas were 1.28 × 10-3mm2/s (95% CI, 1.21-1.34) and 0.86 × 10-3mm2/s (95% CI, 0.69-1.01) for hemispheric glioblastomas with P < .05. CONCLUSIONS: Although no statistically significant difference in diffusion characteristics was found between H3-K27M mutant and H3 wildtype diffuse midline gliomas, lower diffusivity corresponds to a lower survival rate at 1 year after diagnosis. These findings can have an impact on the anticipated clinical course for this patient population and offer providers and families guidance on clinical outcomes.
BACKGROUND AND PURPOSE: Diffuse midline gliomas with histone H3 K27M mutation are biologically aggressive tumors with poor prognosis defined as a new diagnostic entity in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. There are no qualitative imaging differences (enhancement, border, or central necrosis) between histone H3 wildtype and H3 K27M-mutant diffuse midline gliomas. Herein, we evaluated the utility of diffusion-weighted imaging to distinguish H3 K27M-mutant from histone H3 wildtype diffuse midline gliomas. MATERIALS AND METHODS: We identified 31 pediatric patients (younger than 21 years of age) with diffuse gliomas centered in midline structures that had undergone assessment for histone H3 K27M mutation. We measured ADC within these tumors using a voxel-based 3D whole-tumor measurement method. RESULTS: Our cohort included 18 infratentorial and 13 supratentorial diffuse gliomas centered in midline structures. Twenty-three (74%) tumors carried H3-K27M mutations. There was no difference in ADC histogram parameters (mean, median, minimum, maximum, percentiles) between mutant and wild-type tumors. Subgroup analysis based on tumor location also did not identify a difference in histogram descriptive statistics. Patients who survived <1 year after diagnosis had lower median ADC (1.10 × 10-3mm2/s; 95% CI, 0.90-1.30) compared with patients who survived >1 year (1.46 × 10-3mm2/s; 95% CI, 1.19-1.67; P < .06). Average ADC values for diffuse midline gliomas were 1.28 × 10-3mm2/s (95% CI, 1.21-1.34) and 0.86 × 10-3mm2/s (95% CI, 0.69-1.01) for hemispheric glioblastomas with P < .05. CONCLUSIONS: Although no statistically significant difference in diffusion characteristics was found between H3-K27M mutant and H3 wildtype diffuse midline gliomas, lower diffusivity corresponds to a lower survival rate at 1 year after diagnosis. These findings can have an impact on the anticipated clinical course for this patient population and offer providers and families guidance on clinical outcomes.
Authors: Tina Young Poussaint; Sridhar Vajapeyam; Kelsey I Ricci; Ashok Panigrahy; Mehmet Kocak; Larry E Kun; James M Boyett; Ian F Pollack; Maryam Fouladi Journal: Neuro Oncol Date: 2015-10-20 Impact factor: 12.300
Authors: Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin Journal: Radiology Date: 2009-07 Impact factor: 11.105
Authors: W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2011-02-17 Impact factor: 3.825
Authors: Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister Journal: Cancer Cell Date: 2012-10-16 Impact factor: 31.743
Authors: Andrey Korshunov; Marina Ryzhova; Volker Hovestadt; Sebastian Bender; Dominik Sturm; David Capper; Jochen Meyer; Daniel Schrimpf; Marcel Kool; Paul A Northcott; Olga Zheludkova; Till Milde; Olaf Witt; Andreas E Kulozik; Guido Reifenberger; Nada Jabado; Arie Perry; Peter Lichter; Andreas von Deimling; Stefan M Pfister; David T W Jones Journal: Acta Neuropathol Date: 2015-03-10 Impact factor: 17.088
Authors: David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily Journal: Acta Neuropathol Date: 2015-09-23 Impact factor: 17.088
Authors: Hamid Nikbakht; Eshini Panditharatna; Leonie G Mikael; Rui Li; Tenzin Gayden; Matthew Osmond; Cheng-Ying Ho; Madhuri Kambhampati; Eugene I Hwang; Damien Faury; Alan Siu; Simon Papillon-Cavanagh; Denise Bechet; Keith L Ligon; Benjamin Ellezam; Wendy J Ingram; Caedyn Stinson; Andrew S Moore; Katherine E Warren; Jason Karamchandani; Roger J Packer; Nada Jabado; Jacek Majewski; Javad Nazarian Journal: Nat Commun Date: 2016-04-06 Impact factor: 14.919
Authors: James L Leach; James Roebker; Austin Schafer; Joshua Baugh; Brooklyn Chaney; Christine Fuller; Maryam Fouladi; Adam Lane; Renee Doughman; Rachid Drissi; Mariko DeWire-Schottmiller; David S Ziegler; Jane E Minturn; Jordan R Hansford; Stacie S Wang; Michelle Monje-Deisseroth; Paul G Fisher; Nicholas G Gottardo; Hetal Dholaria; Roger Packer; Katherine Warren; Sarah E S Leary; Stewart Goldman; Ute Bartels; Cynthia Hawkins; Blaise V Jones Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: C Jaimes; S Vajapeyam; D Brown; P-C Kao; C Ma; L Greenspan; N Gupta; L Goumnerova; P Bandopahayay; F Dubois; N F Greenwald; T Zack; O Shapira; R Beroukhim; K L Ligon; S Chi; M W Kieran; K D Wright; T Y Poussaint Journal: AJNR Am J Neuroradiol Date: 2020-05-07 Impact factor: 3.825
Authors: C A P F Alves; O Sherbini; F D'Arco; D Steel; M A Kurian; F C Radio; G B Ferrero; D Carli; M Tartaglia; T B Balci; N N Powell-Hamilton; S A Schrier Vergano; H Reutter; J Hoefele; R Günthner; E R Roeder; R O Littlejohn; D Lessel; S Lüttgen; C Kentros; K Anyane-Yeboa; C B Catarino; S Mercimek-Andrews; J Denecke; M J Lyons; T Klopstock; E J Bhoj; L Bryant; A Vanderver Journal: AJNR Am J Neuroradiol Date: 2022-06-30 Impact factor: 4.966
Authors: S C Thust; J A Maynard; M Benenati; S J Wastling; L Mancini; Z Jaunmuktane; S Brandner; H R Jäger Journal: AJNR Am J Neuroradiol Date: 2021-01-07 Impact factor: 3.825